Stock comparison
Collegium Pharmaceutical
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
COLL
Collegium Pharmaceutical
Market cap
$1.11B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | COLL | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 46D | 75B | IDXX |
| Benjamin Graham | 62D | 80A | IDXX |
| Philip Fisher | 40D | 75B | IDXX |
| Peter Lynch | 53D | 71B | IDXX |
| Joel Greenblatt | 28F | 83C | IDXX |
| Charlie Munger | 44D | 87A | IDXX |
| Terry Smith | 43D | 84A | IDXX |
Side-by-side metrics
| Metric | COLL | IDXX |
|---|---|---|
| Market cap | $1.11B | $44.12B |
| P/E (TTM) | 15.5x | 39.0x |
| EV/EBIT | 9.1x | 31.6x |
| ROIC (TTM) | 10.51% | 40.66% |
| Gross margin | 60.68% | 62.05% |
| Net margin | 9.41% | 24.63% |
| Revenue CAGR 5y | 29.58% | 7.56% |
| EPS CAGR 5y | -0.86% | 10.79% |
| Debt / Equity | 2.6x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
COLL leads on
- Revenue CAGR 5y29.58%vs 7.56%+74%
- EV/EBIT9.1xvs 31.6x+71%
- P/E (TTM)15.5xvs 39.0x+60%
IDXX leads on
- EPS CAGR 5y10.79%vs -0.86%+108%
- Market cap$44.12Bvs $1.11B+97%
- ROIC (TTM)40.66%vs 10.51%+74%
- Debt / Equity0.7xvs 2.6x+73%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.